LASA SUPERGENERICS LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24 INR | +0.21% |
|
+1.27% | -19.73% |
| Apr. 26 | Lasa Supergenerics CFO Steps Down | MT |
| Apr. 26 | Lasa Supergenerics Limited Announces Resignation of Ravi Shankar Kabra as Chief Financial Officer | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 1.37B 16.43M | Sales 2023 | 1.3B 15.53M | Capitalization | 929M 11.14M |
|---|---|---|---|---|---|
| Net income 2022 | -53M -635K | Net income 2023 | -386M -4.63M | EV / Sales 2022 | 1.26 x |
| Net Debt 2022 | 29.79M 357K | Net Debt 2023 | 196M 2.35M | EV / Sales 2023 | 0.87 x |
| P/E ratio 2022 |
-31.7
x | P/E ratio 2023 |
-2.41
x | Employees | 89 |
| Yield 2022 |
0.6% | Yield 2023 |
-
| Free-Float | 35.97% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.21% | ||
| 1 week | +1.27% | ||
| Current month | -6.25% | ||
| 1 month | -3.23% | ||
| 3 months | -22.20% | ||
| 6 months | -6.25% | ||
| Current year | -19.73% |
1 week
22.50
24.50
1 month
22.5026.90
Current year
21.5041.20
1 year
20.6041.20
3 years
17.1092.90
5 years
9.45100.90
10 years
9.45214.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 43 | 16-03-10 | |
Sunil Sitale
ADM | Chief Administrative Officer | - | - |
| Compliance Officer | 37 | 23-03-20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 43 | 16-03-10 | |
| Director/Board Member | 63 | 17-05-01 | |
| Director/Board Member | 35 | 17-05-01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-15 | 24 | +0.21% | 14,987 |
| 24-05-14 | 23.95 | +0.21% | 14,726 |
| 24-05-13 | 23.9 | +4.82% | 16,678 |
| 24-05-10 | 22.8 | -1.72% | 52,654 |
| 24-05-09 | 23.2 | -2.11% | 19,259 |
End-of-day quote NSE India S.E., May 14, 2024
More quotes
Lasa Supergenerics Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (API) bulk drugs products. The Company is engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, pharmaceuticals, drugs, and others. It is specialized in catalyst chemistry and manufactures anthelmintic/ veterinary API products with the production capabilities and product categories in India. The Company's products include API products, other API products, animal feed ingredients and reagents for therapeutic use. Its API products include Fenbendazole, Toldimphos sodium, Cyromazine, Albendazole, Riclabendazole, Rafoxanide, Ornidazole, 2,6-Diiodo-4-Nitrophenol, Ricobendazole, Oxfendazole, Closantel Base, Closantel sodium, Nitroxynil, Halquinol, and Oxyclozanide. The Company's manufacturing facility is located at Chiplun, Maharashtra.
Sector
Pharmaceuticals
Calendar
2024-05-26
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -19.73% | 14.41M | |
| -12.21% | 79.07B | |
| +25.25% | 3.72B | |
| +1.39% | 3.33B | |
| +16.39% | 1.71B | |
| -8.73% | 1.52B | |
| -23.19% | 1.29B | |
| -3.32% | 1.29B | |
| -12.66% | 1.15B | |
| +0.24% | 1.05B |
- Stock Market
- Equities
- LASA Stock